SecBot SecBot
8-K ·Filed Nov 9, 2026

SYK

STRYKER CORP
NEUTRAL
Impact 2/10
Horizonimmediate Processed8d 5h ago SEC0001193125-26-453635
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Monitor for any future committee assignments or strategic shifts that may reflect Mr. Davis's healthcare diagnostics expertise. No immediate financial or operational read-through from this board addition.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$324.29
T+0 close · Nov 9, 2026 · via day close
Latest settled
−2.08%
T+5 · $317.54
Vs SPY
+0.25%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 10 $324.29entry
  2. T+1 · 7d ago −1.70%α −3.01% · $318.79
  3. T+5 · 14h ago −2.08%α +0.25% · $317.54
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Stryker announced the nomination of James E. Davis, Chairman, CEO and President of Quest Diagnostics, to its board of directors, effective January 1, 2027. The board was expanded from 11 to 12 members to accommodate his election. This is a routine board addition with no financial terms disclosed.

Key Facts

  • Board of Directors increased authorized directors from 11 to 12 and elected James E. Davis to fill the vacancy
  • Mr. Davis's election becomes effective January 1, 2027
  • Mr. Davis is Chairman, CEO and President of Quest Diagnostics
  • Mr. Davis will be compensated consistent with other non-employee directors as described in the 2026 proxy statement
  • No committee assignments have been made for Mr. Davis at this time

Financial Impact

No financial impact disclosed; director compensation consistent with standard non-employee director pay

Risk Factors

  • No material risks identified from this routine board appointment

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
77% bullish (35 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-453635
Document: d101928dex991.htm0001193125-26-453635
Document: 0001193125-26-453635-index-headers.html0001193125-26-453635
Document: 0001193125-26-453635-index.html0001193125-26-453635
Document: 0001193125-26-453635.txt0001193125-26-453635

Track record

29 reports on SYK

Performance horizon

5 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +23.40% at T+20 after the Oct 7, 2026 report. 7 of 11 went positive at some point.

Filters
  1. Nov 12, 20266d ago Court Ruling Neutral 3/10 Entry $309.64 Now $310.72 +0.35% settles Dec 14
  2. Nov 9, 20268d ago 8-K Neutral 2/10 Viewing Entry $324.29 Now $310.72 −4.18% settles Dec 9
  3. Nov 5, 202612d ago 144 Neutral 3/10 Entry $325.87 Now $310.72 −4.65% settles Dec 7
  4. Nov 4, 202613d ago S-3ASR Neutral 3/10 Entry $335.08 Now $310.72 −7.27% settles Dec 4
  5. Nov 3, 202614d ago Institutional Cluster Mixed 3/10 Entry $310.55 Now $310.72 +0.05% settles Dec 2
  6. Oct 29, 202619d ago 8-K Bearish 6/10 No price data
  7. Oct 29, 202619d ago Press Release Bearish 6/10 Entry $291.86 Now $310.72 −6.46% settles Nov 30
  8. Oct 26, 202622d ago Press Release Neutral 4/10 Entry $306.13 Now $310.72 +1.50% settles Nov 23
  9. Oct 20, 202629d ago PTAB Trial Bearish 5/10 Entry $297.60 Now $310.72 −4.41% settles Nov 18
  10. Oct 7, 20265w ago ANALYST-UPGRADE Bullish 4/10 Entry $275.25 to $339.65 Now $310.72 +12.89% ▲ +23.40% +24.74% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens Thu (12h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026